Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs MasTec Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.5 (market cap $31.07B), while MasTec Inc trades at $191.08 (market cap $16.55B). The key difference: GE HealthCare Technologies Inc. Common Stock is the larger of the two by market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| GEHC | MTZ | |
|---|---|---|
Market Cap | $31.07B | $16.55B |
Volume | 3,443,020 | 1,530,865 |
Sector | Health | Industrials |
52-Week High | $88.16 | $437.51 |
52-Week Low | $59.48 | $190.08 |
Enterprise Value | $39.53B | $19.47B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 25 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
MasTec (MTZ) trades at $206.12, down 0.35% on the day, with technical indicators showing bearish momentum below key moving averages. The company reported strong revenue growth from $14.3B in 2025 to $16.1B in 2026, with net income improving to $494M. Recent news highlights MTZ's record $21.4B backlog and positioning in AI infrastructure and power delivery markets, though cash flow volatility and premium valuation pose challenges.
Wall Street maintains strong bullish sentiment with 89% buy ratings and a $403.92 consensus price target, representing 96% upside potential. Key opportunities include infrastructure investment cycles and data center expansion, while risks include execution challenges, communications segment softness, and elevated P/E ratio of 32.8x.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
